Stock Events

Stock Events

Scopus Biopharma 

$0
11
+$0+0% Thursday 19:16

Statistics

Day High
0
Day Low
0
52W High
0.01
52W Low
0
Volume
47,076
Avg. Volume
2,412
Mkt Cap
16,833.6
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

3JunExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2018
2019
2020
2021
2022
0Revenue
-23.22MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SCPS. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics focuses on gene editing, directly competing with Scopus Biopharma's gene therapy and editing technologies.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine operates in the gene editing space, targeting similar therapeutic areas as Scopus Biopharma.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics is a leading developer of CRISPR gene editing treatments, overlapping with Scopus Biopharma's focus areas.
Beam Therapeutics
BEAM
Mkt Cap2.53B
Beam Therapeutics specializes in base editing, a form of gene editing that competes with Scopus Biopharma's technologies.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics works on genome editing and gene therapy, directly competing with Scopus Biopharma's research and development efforts.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals focuses on RNAi therapeutics, which can be seen as a competing platform to Scopus Biopharma's gene-based therapies.
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, competing in the broader gene therapy market.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals, including gene therapies, competing in similar therapeutic areas.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals, while broader in scope, invests in CRISPR and other genetic therapies, potentially competing in specific areas of interest.

About

Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. The company lead development programs are immuno-oncology gene therapy for the treatment of various cancers. It offers Duet Platform, a CpG signal transducer and activator of transcription 3 (STAT3) inhibitors; and MRI-1867, rationally designed, orally available, dual-action, hybrid, and small molecule that is an inverse agonist of the endocannabinoid system/cannabinoid receptor 1, as well as an inhibitor of inducible nitric oxide synthase. Scopus BioPharma Inc. has strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem for its lead development and other programs. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.
Show more...
CEO
Mr. Ira Scott Greenspan
Employees
13
Country
US
ISIN
US8091711015

Listings

OTC Link
US
SCPS

0 Comments

Share your thoughts

FAQ

What is Scopus Biopharma stock price today?▼
The current price of SCPS is $0 USD — it has increased by +0% in the past 24 hours. Watch Scopus Biopharma stock price performance more closely on the chart.
What is Scopus Biopharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Scopus Biopharma stocks are traded under the ticker SCPS.
What is Scopus Biopharma market cap?▼
Today Scopus Biopharma has the market capitalization of 16,833.6
When is the next Scopus Biopharma earnings date?▼
Scopus Biopharma is going to release the next earnings report on June 03, 2026.
What is Scopus Biopharma revenue for the last year?▼
Scopus Biopharma revenue for the last year amounts to 0 USD.
What is Scopus Biopharma net income for the last year?▼
SCPS net income for the last year is -23.22M USD.
How many employees does Scopus Biopharma have?▼
As of April 01, 2026, the company has 13 employees.
In which sector is Scopus Biopharma located?▼
Scopus Biopharma operates in the Health Care sector.
When did Scopus Biopharma complete a stock split?▼
The last stock split for Scopus Biopharma was on June 04, 2007 with a ratio of 1:20.
Where is Scopus Biopharma headquartered?▼
Scopus Biopharma is headquartered in New York, US.